PMID: 42213275

The role of 18 F-FDG PET/CT SUVmax values in evaluating treatment response in hormone receptor-positive metastatic breast cancer patients receiving CDK4/6 inhibitor therapy.

Özbek Rahime Dilara, Aytekin Aydın, Yerdes Enes, Elboga Umut

Annals of nuclear medicine · 2026

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.

The role of 18&#xa0;F-FDG PET/CT SUVmax values in evaluating treatment response in hormone receptor-positive metastatic breast cancer patients receiving CDK4/6 inhibitor therapy.